Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Clinical and genomic features of Chinese lung cancer patients with germline mutations

PROVIDER: PRJEB41076 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	C0001.mutect2.vcf.gz	Vcf
	C0001.mutect2.vcf.gz.tbi	Vcf
	C0002.mutect2.vcf.gz	Vcf
	C0002.mutect2.vcf.gz.tbi	Vcf
	C0003.mutect2.vcf.gz	Vcf

Items per page:

1 - 5 of 3588

Similar Datasets

Proteomic and phosphoproteomic maps of lung squamous cell carcinoma from Chinese patients

Project description:Lung cancer in Chinese patients has distinct genomic features and lung squamous cell carcinoma (LUSC) has limited biomarkers for targeted therapy even though a lot of progress has been made in genomics research. Systematical research on LUSC at protein level will be beneficial to improve precision medicine. In this study, the large scale proteomics and phosphoproteomics analysis on clinical Chinese LUSC patients were performed.

2020-05-16 | PXD019234 |

Project description:Germline mutations in lung cancer

| PRJNA613408 | ENA

Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients

Project description:Chinese lung cancer patients have distinct epidemiologic and genomic features, highlighting the presence of specific etiologic mechanisms other than smoking. We integrate genomic (whole-genome sequencing, WGS) and transcriptome (polyA-enriched RNASeq) sequencing from 92 NSCLC cases and comprehensively identified the distinct genomic features of Chinese NSCLC patients. We reveal that inflammatory infiltration may contribute to the accumulation of EGFR mutations, especially in never-smokers.

| EGAS00001002954 | EGA

Clinical and genomic features of Chinese lung cancer patients with germline mutations

Project description:This cohort included NGS data of a panel on 1021 cancer related gene from paired cancer-normal samples of 1794 Chinese lung cancer patients, including 44 SCLC patients and 1750 non-small cell lung cancer patients. According to ACMG 2015 guideline, pathogenic germline mutations were annotated and manually verified.

2022-07-06 | PRJEB41076 | EVA

Integrative proteomic characterization of human lung adenocarcinoma

Project description:Genomic studies of lung adenocarcinoma (LUAD) have advanced understanding of the disease’s biology and accelerated targeted therapy. However, proteomic characteristics of LUAD remain poorly understood. We carried out comprehensive proteomic analysis of 103 cases of LUAD in Chinese patients. Integrative analysis of proteome, phosphoproteome, transcriptome, and whole-exome sequencing data revealed cancer associated characteristics, such as tumor-associated protein variants, distinct proteomic features, and clinical outcomes in patients of early stage or with EGFR and TP53 mutations. Proteome-based stratification of LUAD revealed three subtypes (S-I, S-II, S-III) related to different clinical and molecular features. Further, we nominated potential drug targets and validated the plasma protein level of HSP 90β as a potential prognostic biomarker for LUAD in an independent cohort. Our integrative proteomic analysis gives a more comprehensive understanding on the molecular landscape of LUAD and offers the opportunity for more precise diagnosis and treatment.

| PXD020252 |

Large genomic alteration of 7q in two patients with multiple primary cancers, including triple negative breast cancer, and family history of malignant neoplasms

2016-02-15 | GSE77138 | GEO

Large genomic alteration of 7q in two patients with multiple primary cancers, including triple negative breast cancer, and family history of malignant neoplasms

Project description:A great percentage of patients with multiple primary cancers (MPCs) and family history of cancer are suspected to have a hereditary cancer predisposition syndrome. However, only a small proportion of these cases are explained by mutations in high-penetrance genes, suggesting the involvement of undiscovered genes in cancer predisposition. In this study, we report the molecular and clinical characterization of two unrelated patients with MPCs, a positive family history of cancer, no germline pathogenic mutations in BRCA1, BRCA2 and TP53 genes and large genomic rearrangements mapped on chromosome 7q. Genomic rearrangements were assessed with Affymetrix CytoScan HD Array platform in two unrelated patients (Patient 1 and Patient 2) with multiple primary cancers. Additionally, the mother of Patient 2 and four children (the son of Patient 1 and three children of Patient 2) were also evaluated.

2016-02-15 | E-GEOD-77138 | biostudies-arrayexpress

The RNAseq of 79 small cell lung cancer (sclc) and 7 normal control

Project description:Even though small cell lung cancer (SCLC) has entered the age of broad genomic analysis, platinum-based chemotherapy remains the standard care for SCLC. Topotecan is the only approved agent for recurrent or progressive SCLC (1). In the absence of well-defined genomic biomarkers, clinical efficacy signals in genomically distinct subsets of SCLC could have been missed. Serine/Arginine Splicing Factor 1 (SRSF1) is a member of SR protein family. The deleterious consequences of overexpression of the SRSF1 proto-oncogene in human cancers suggest that there are complex mechanisms and pathways underlying SRSF1-mediated transformation (2). Whole exome and transcriptome sequencing of primary tumor SCLC from 99 Chinese patients has identified SRSF1 DNA amplification and mRNA over-expression which predicts poor survival in Chinese SCLC patients. In vitro and in vivo studies have demonstrated that SRSF1 is essential for tumorigenecity of SCLC and plays a key role in DNA repair and chemo-sensitivity. We did RNAseq on 79 small cell lung cancer patients' tumor sample and 7 normal lung tissue. We normalized the RNAseq data and did differential expression analysis. The deleterious consequences of overexpression of the SRSF1 proto-oncogene in human cancers suggest that there are complex mechanisms and pathways underlying SRSF1-mediated transformation.

2016-02-10 | E-GEOD-60052 | biostudies-arrayexpress

Molecular Profiling Provides Clinical Insights into Targeted and Immunotherapies as well as Prognosis for Colorectal Cancer

Project description:Background and aims Tumor genetic testing is indispensable in the management of primary and advanced colorectal cancer, with one-third of patients progressing despite standard care. We aimed to refine the indications for genomics-guided precision therapy. Methods We prospectively sequenced 869 tumors from Chinese patients with colorectal cancer and performed a comprehensive analysis of clinical and genomic profiles. The clinical significance of single mutation and co-occurring events was assessed in metastatic colorectal cancer (mCRC). The tumor immune microenvironment was evaluated by Immunoscore assay and single-cell sequencing. Results Single gene somatic mutations in BRAF and RBM10 were associated with shorter progression-free survival (PFS) in treatment-naive mCRC patients (BRAF: hazard ratio [HR] = 2.2 [95% CI, 1.1-4.4]; RBM10: HR= 6.8 [95% CI, 2.6-17.3]), and RBM10 remained a risk factor irrespective of the addition of bevacizumab to the chemotherapy regimens. KRAS mutations coexisting with those in AMER1 or APC were enriched in the metastatic cohort (26.23%), which had poor PFS and did not benefit from bevacizumab. 40 patients (4.6%) carried pathogenic or likely pathogenic germline alterations in the DNA damage repair pathway and 30% of them had double-hit events in the tumor with higher MSI scores. High tumor indel burden with MSI-high suggested a large number of tumor-infiltrating lymphocytes, whereas POLE-mutant with TMB-ultrahigh indicated a relatively quiescent immunophenotype. The heterogeneous genomic-immunological ecosystem was reflected in the divergent antigen presentation, immune checkpoint protein expression and responses of T cells to pembrolizumab treatment. Conclusion Integrated analysis of the clinical, genomic, and immunological profiles of colorectal cancer provides insights into prognostic stratification, drug response and potential clinical trials.

2023-01-10 | GSE222202 | GEO

Proteogenomic landscape of the Esophageal Squamous Cell Cancer reveals the lipid droplet formation process as a novel therapeutic target

Project description:The integrated proteogenomic analysis revealed proteomic characteristics associated with genomic variants and clinical features including arm or focal amplifications, SNV mutations, tumor size, lymph node metastasis, smoking history.

2025-03-24 | PXD062163 |

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data